Metrics as of 10/16/2026, 01:42 AM (Berlin time), refresh in progress.
Cue Biopharma Stock
Cue Biopharma, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Shao-Lee Lin
- Employees
- 29
- Market cap
- $136 M
- IPO
- 02/01/2018
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The…
Cue Biopharma stock: price history
1D
+0.4%
1W
-16.4%
1M
-41.0%
6M
+1.1%
YTD
+103.8%
1Y
-20.7%
2Y
-44.4%
5Y
-95.1%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~10% stronger price swings than usual
Ask the agents about Cue Biopharma
Analyst assessment of Cue Biopharma
PRICE TARGET LOW
US$83.00
CONSENSUS
US$83.00
MEDIAN
US$83.00
PRICE TARGET HIGH
US$83.00
0
STRONG BUY
9
BUY
0
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 02/04/2025
Cue Biopharma stock metrics
P/E
-0.69
P/B
51.25
EV/EBITDA
-1.33
RETURN ON EQUITY
-6,626.3%
NET MARGIN
-1,943.2%
DEBT/EQUITY
3.81
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.4%
FLOAT SHARES
6,424,430
AVG. DAILY VOLUME (30D)
369,044
Insider transactions (SEC)
Lin Shao-Lee
Ray Sumita
Meluzio Michael Vincent
Lin Shao-Lee
Ray Sumita
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Cue Biopharma stock
What does Cue Biopharma do?
Cue Biopharma, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Shao-Lee Lin, the company employs around 29 people.
The IPO was on 02/01/2018; the stock trades on NASDAQ under the ticker CUE.
What do analysts say about Cue Biopharma stock?
9 analysts rate the stock, the consensus is Buy (as of 02/04/2025).
The average price target is US$83.00, ranging from US$83.00 to US$83.00, with a median of US$83.00.
This is an external assessment, not a statement by Market Jury.
When does Cue Biopharma report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 10% stronger than usual.
Does Cue Biopharma pay a dividend?
No, Cue Biopharma currently does not pay a dividend.
Which stocks are comparable to Cue Biopharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Cue Biopharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cue Biopharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.